Physician profile
Robert Paull
NPI 1427181270
$24,898.16
in general payments reported to CMS, 2019-2025
32 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,805 · 2020: $2,616 · 2021: $1,544 · 2022: $1,826 · 2023: $1,798 · 2024: $2,104 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $6,131 · Travel and Lodging: $686 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,050.00 |
| Food and Beverage | $6,130.57 |
| Travel and Lodging | $686.08 |
| Education | $240.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,741.91 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $2,242.99 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,536.68 | 2019-2025 | |
| Abbvie INC. | $1,511.86 | 2019-2025 | |
| Janssen Biotech, INC. | $1,251.51 | 2019-2025 | Tremfya |
| Convatec INC. | $990.72 | 2025 | |
| Incyte Corporation | $851.62 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $736.17 | 2019-2025 | Adbry, Anzupgo |
| Almirall LLC | $541.94 | 2020-2025 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $526.54 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $523.43 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $492.38 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $480.17 | 2020-2022 | |
| Pfizer INC. | $459.94 | 2019-2025 | |
| Lilly USA, LLC | $417.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $306.60 | 2019-2020 | |
| Dermavant Sciences, INC. | $268.65 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $207.33 | 2024-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $135.36 | 2025 | Acthar |
| Journey Medical Corporation | $116.82 | 2020 | |
| Sun Pharmaceutical Industries INC. | $114.53 | 2019-2025 | |
| Dermira, INC. | $111.63 | 2019 | |
| Vyne Pharmaceuticals INC. | $105.15 | 2020 | |
| Mayne Pharma Commercial LLC | $83.63 | 2020-2023 | |
| Celgene Corporation | $33.75 | 2024-2025 | Sotyktu |
| Genentech USA, INC. | $30.58 | 2024 | Erivedge |
| Botanix Sb INC | $17.35 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $14.83 | 2019 | |
| Amgen INC. | $12.68 | 2020 | |
| Biofrontera INC. | $11.55 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.27 | 2020 | |
| Novum Pharma, LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Paull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.